Centessa Pharmaceuticals (CNTA) Assets Average (2021 - 2026)

Centessa Pharmaceuticals (CNTA) has 6 years of Assets Average data on file, last reported at $664.6 million in Q1 2026.

• Assets Average for Q1 2026 came in at $664.6 million, up 20.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $664.6 million (up 20.33% YoY), and the FY2025 annual result was $632.1 million, up 34.92% from the prior year.
• Assets Average advanced to $664.6 million in Q1 2026 per CNTA's latest filing, from $567.9 million in the prior quarter.
• Over five years, Assets Average peaked at $664.6 million in Q1 2026 and troughed at $344.2 million in Q1 2024.
• A 5-year average of $486.3 million and a median of $500.2 million in 2022 frame the typical range for Assets Average.
• The sharpest annual moves came in 2023 and 2024: Assets Average plunged 30.01% in 2023, then soared 60.86% in 2024.
• A 5-year view of Assets Average shows it stood at $461.8 million in 2022, then decreased by 20.14% to $368.8 million in 2023, then soared by 60.86% to $593.3 million in 2024, then slipped by 4.27% to $567.9 million in 2025, then increased by 17.03% to $664.6 million in 2026.
• Business Quant data shows CNTA's Assets Average at $664.6 million in Q1 2026, $567.9 million in Q4 2025, and $470.2 million in Q3 2025.